These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7873459)

  • 21. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1623-8. PubMed ID: 10553421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
    Gallacher SJ; Ralston SH; Fraser WD; Dryburgh FJ; Cowan RA; Logue FC; Boyle IT
    Bone Miner; 1991 Dec; 15(3):249-56. PubMed ID: 1773137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
    Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
    Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
    Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
    Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
    Mechanick JI; Liu K; Nierman DM; Stein A
    J Spinal Cord Med; 2006; 29(4):406-12. PubMed ID: 17044392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
    Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
    J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
    Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
    Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
    Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and compliance of intravenous and oral dosing regimens.
    Jackson G
    Oncologist; 2005 May; 10(5):313-4; author reply 315-6. PubMed ID: 15851784
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pamidronate in treatment of pain caused by bone metastasis].
    Wang DJ; Liu HQ; Ren J; Chen YL; Zhan QY; Cai Y; Liu MZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1467-9. PubMed ID: 15566659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate safety and tolerability.
    Body JJ
    Oncologist; 2005 May; 10(5):317; author reply 318-9. PubMed ID: 15851786
    [No Abstract]   [Full Text] [Related]  

  • 35. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
    Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
    Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.